NeuroVive Pharmaceutical

www.neurovive.com
Lund, Sweden

Time filter

Source Type

The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.


Patent
NeuroVive Pharmaceutical | Date: 2015-04-08

The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Krebs cycle. Not all Krebs cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.


Patent
NeuroVive Pharmaceutical | Date: 2015-04-08

The present invention provides novel cell-permeable succinates and cell permeable precursors of succinateaimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Krebs cycle. Not all Krebs cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.


Patent
NeuroVive Pharmaceutical | Date: 2017-02-15

The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Krebs cycle. Not all Krebs cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.


Patent
NeuroVive Pharmaceutical | Date: 2017-02-15

The present invention provides novel cell-permeable succinates and cell permeable precursors of succinate aimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Krebs cycle. Not all Krebs cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.


Patent
NeuroVive Pharmaceutical | Date: 2013-10-04

A novel method useful in drug screening. The method is useful for testing effects of substances on the mitochondria, notably toxic or beneficial effects of drug substances or candidate drug substances. The method is based on measurement in live human mitochondria ex vivo, but in a setting as near the in vivo situation as possible. The method is also useful for testing substances impact on the mitochondrial respiration. The method can be used to i) screening and selection of early or late stage drug candidates in cells derived from blood from healthy individuals or in so-called buffy coat, which is a concentrated solution of platelets and white blood cells, ii) testing a patients sensitivity to a known mitochondrial toxicant, iii) analysing mitochondrial drug toxicity in clinical trials, and/or iv) analysing beneficial effects of drugs intended to improve mitochondrial function


Patent
NeuroVive Pharmaceutical | Date: 2015-03-04

The present invention relates to cyclosporine emulsions containing: (i) a cyclosporine, (ii) a natural oil (long chain triglyceride), (iii) a phosphatidylcholine, (iv) glycerol, (v) a pharmaceutically tolerable alkali salt of a free fatty acid, (vi) a medium chain triglyceride-oil, (vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment and (viii) water, and to therapeutic methods using them.


Patent
NeuroVive Pharmaceutical | Date: 2012-03-29

There is provided inter alia compounds of formula (I): for use in treatment of viral infection or as an immunosuppressant.


Patent
NeuroVive Pharmaceutical | Date: 2011-12-20

There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.


Patent
NeuroVive Pharmaceutical | Date: 2012-10-24

There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.

Loading NeuroVive Pharmaceutical collaborators
Loading NeuroVive Pharmaceutical collaborators